Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 48, Issue 2, 2015, Pages 319-353

  Harris, Steven A ^a   Harris, Elizabeth A ^b  

^a St Vincent Medical Group   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; amyloid; ApoE4; Cytomegalovirus; dementia; Herpes simplex; neurodegeneration; pathogen

Indexed keywords

ACICLOVIR; AMOXICILLIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; AZITHROMYCIN; BISMUTH; CEFALOTIN; CEFTRIAXONE; CIDOFOVIR; CLARITHROMYCIN; CYTOKINE; DOXYCYCLINE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAMYCIN; TAU PROTEIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; VALACICLOVIR; VALGANCICLOVIR;

ADAPTIVE IMMUNITY; AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; APOPTOSIS; BACTERIAL VIRULENCE; BLOOD BRAIN BARRIER; BORRELIA BURGDORFERI; BRAIN; BRAIN INFECTION; BRAIN LEVEL; CHLAMYDIA PNEUMONIAE; CHLAMYDIAL PNEUMONIA; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENTAL PROCEDURE; DISEASE EXACERBATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLIA CELL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPESVIRIDAE; HETEROZYGOTE; HUMAN; HUMAN HERPESVIRUS 6; HUMORAL IMMUNITY; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOLECULAR PATHOLOGY; MOUTH HYGIENE; NERVE CELL LESION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGEN LOAD; PERIODONTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPIROCHETE; SPIROCHETE INFECTION; TREPONEMA; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REACTIVATION; ANIMAL; COMPLICATION; MICROBIOLOGY; PATHOPHYSIOLOGY; VIROLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS;

EID: 84941266767     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142853     Document Type: Review

References (274)

1. Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol 29, 357-365.
2. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer's disease. Subcell Biochem 65, 329-352.
3. Wozniak MA, Mee AP, Itzhaki RF (2009) Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol 217, 131-138.
4. Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Itzhaki RF (1991) Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J Med Virol 33, 224-227.
5. Miklossy J (2011) Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med 13, e30.
6. Balin BJ, Gérard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP (1998) Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol 187, 23-42.
7. Gérard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, Frey WH 2nd, Bordayo EZ, Whittum Hudson JA, Hudson AP (2006) Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol 48, 355-366.
8. Miklossy J, Kasas S, Janzer RC, Ardizzoni F, Van der Loos H (1994) Further ultrastructural evidence that spirochaetes may play a role in the etiology of Alzheimer's disease. Neuroreport 5, 1201-1204.
9. Miklossy J (1993) Alzheimer's disease-a spirochetosis? Neuroreport 4, 841-848.
10. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB (2007) Herpes simplex virus infection causes cellular β amyloid accumulation and secretase up-regulation. Neurosci Lett 429, 95-100.
11. Wozniak MA, Frost AL, Itzhaki RF (2009) Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis 16, 341-350.
12. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM (2004) Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 25, 419-429.
13. Miklossy J, Kis A, Radenovic A, Miller L, Forro L, Martins R, Reiss K, Darbinian N, Darekar P, Mihaly L, Khalili K (2006) Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging 27, 228-236.
14. Ramesh G, Alvarez AL, Roberts ED, Dennis VA, Lasater BL, Alvarez X, Philipp MT (2003) Pathogenesis of Lyme neuroborreliosis: Borrelia burgdorferi lipoproteins induce both proliferation and apoptosis in rhesus monkey astrocytes. Eur J Immunol 33, 2539-2550.
15. Boelen E, Steinbusch HW, Bruggeman CA, Stassen FR (2009) The inflammatory aspects of Chlamydia pneumoniae-induced brain infection. Drugs Today (Barc) 45(Suppl B), 159-164.
16. Ramesh G, Borda JT, Dufour J, Kaushal D, Ramamoorthy R, Lackner AA, Philipp MT (2008) Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis. Am J Pathol 173, 1415-1427.
17. Lokensgard JR, Hu S, Sheng W, van Oijen M, Cox D, Cheeran MC, Peterson PK (2001) Robust expression of TNF alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus. J Neurovirol 7, 208-219.
18. Halford WP, Gebhardt BM, Carr DJ (1996) Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1. J Immunol 157, 3542-3549.
19. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, a006346.
20. Ho GJ, Drego R, Hakimian E, Masliah E (2005) Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 4, 247-256.
21. Dosunmu R, Wu J, Basha MR, Zawia NH (2007) Environmental and dietary risk factors in Alzheimer's disease. Expert Rev Neurother 7, 887-900.
22. Itzhaki RF (2011) Herpes simplex and Alzheimer's-Time to Think Again? Alzforum, http://www.alzforum.org/webinars/herpes-simplex-and-alzheimers-time-thinkagain?liveID=188, Posted 24 Feb 2011, Accessed on March 3, 2013.
23. Ball MJ (1982) Limbic predilection in Alzheimer dementia: Is reactivated herpes virus involved? Can J Neurol Sci 9, 303-306.
24. McQuaid S, Allen IV, McMahon J, Kirk J (1994) Association of measles virus with neurofibrillary tangles in subacute sclerosing panencephalitis: A combined in situ hybridization and immunocytochemical investigation. Neuropathol Appl Neurobiol 20, 103-110.
25. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111, 529-538.
26. Strandberg T, Pitkala K, Linnavuori K, Tilvis R (2003) Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular disease. Stroke 34, 2126-2131.
27. Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, Elkind MS (2013) Infectious burden and cognitive function: The Northern Manhattan Study. Neurology 80, 1209-1215.
28. Strandberg TE, Aiello AE (2013) Is the microbe-dementia hypothesis finally ready for a treatment trial? Neurology 80, 1182-1183.
29. Letenneur L, Péres K, Fleury H, Garrigue I, Barberger-Gateau P (2008) Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: A populationbased cohort study. PLoS One 3, e3637.
30. Lövheim H, Gilthorpe J, Adolfsson R, Nilsson LG, Elgh F (2015) Reactivated herpes simplex infection increases the risk of Alzheimer's disease. Alzheimers Dement 11, 593-599.
31. Kobayashi N, Nagata T, Shinagawa S, Oka N, Shimada K, Shimizu A, Tatebayashi Y, Yamada H, Nakayama K, Kondo K (2013) Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. Biochem Biophys Res Commun 430, 907-911.
32. Itzhaki RF (2014) Herpes simplex virus type 1 and Alzheimer's disease: Increasing evidence for a major role of the virus. Front Aging Neurosci 6, 202.
33. Lövheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F (2015) Herpes simplex infection and the risk of Alzheimer's disease-A nested case-control study. Alzheimers Dement 11, 587-592.
34. Schretlen DJ, Vannorsdall TD, Winicki JM, Mushtaq Y, Hikida T, Sawa A, Yolken RH, Dickerson FB, Cascella NG (2010) Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. Schizophr Res 118, 224-231.
35. Prasad KM, Watson AM, Dickerson FB, Yolken RH, Nimgaonkar VL (2012) Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. Schizophr Bull 38, 1137-1148.
36. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH (2003) Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 60, 466-472.
37. Shirts BH, Prasad KM, Pogue-Geile MF, Dickerson F, Yolken RH, Nimgaonkar VL (2008) Antibodies to cytomegalovirus and herpes simplex virus 1 associated with cognitive function in schizophrenia. Schizophr Res 106, 268-274.
38. Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB (2011) Serological evidence of exposure to herpes simplex virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res 128, 61-65.
39. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R (2012) Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res 134, 83-88.
40. Mancuso R, Baglio F, Cabinio M, Calabrese E, Hernis A, Nemni R, Clerici M (2014) Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer's disease. J Alzheimers Dis 38, 741-745.
41. Itzhaki R (2004) Herpes simplex virus type 1, apolipoprotein E and Alzheimer's disease. Herpes 11(Suppl 2), 77A-82A.
42. Jamieson GA, Maitland NJ, Wilcock GK, Yates CM, Itzhaki RF (1992) Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J Pathol 167, 365-368.
43. Mori I, Kimura Y, Naiki H, Matsubara R, Takeuchi T, Yokochi T, Nishiyama Y (2004) Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease. J Med Virol 73, 605-611.
44. Rodriguez JD, Royall D, Daum LT, Kagan-Hallet K, Chambers JP (2005) Amplification of herpes simplex type 1 and human herpes type 5 viral DNA from formalin-fixed Alzheimer brain tissue. Neurosci Lett 390, 37-41.
45. Itabashi S, Arai H, Matsui T, Higuchi S, Sasaki H (1997) Herpes simplex virus and risk of Alzheimer's disease. Lancet 349, 1102.
46. Hemling N, RöyttäM, Rinne J, Pöllänen P, Broberg E, Tapio V, Vahlberg T, Hukkanen V (2003) Herpesviruses in brains in Alzheimer's and Parkinson's diseases. Ann Neurol 54, 267-271.
47. Marques AR, Straus SE, Fahle G, Weir S, Csako G, Fischer SH (2001) Lack of association between HSV-1DNA in the brain, Alzheimer's disease and apolipoprotein E4. J Neurovirol 7, 82-83.
48. Wozniak MA, Shipley SJ, Combrinck M, Wilcock GK, Itzhaki RF (2005) Productive herpes virus in brain of elderly normal subjects and Alzheimer's disease patients. J Med Virol 75, 300-306.
49. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 349, 241-244.
50. Lin WR, Graham J, MacGowan SM, Wilcock, GK, Itzhaki, RF (1998) Alzheimer's disease, herpes virus in brain, apolipoprotein E4 and herpes labialis. Alzheimers Rep 1, 173-178.
51. Burgos J, Ramirez C, Sastre I, Valdivieso F (2006) Effect of Apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J Virol 80, 5383-5387.
52. Guzman-Sanchez F, Valdivieso F, Burgos JS (2012) Agingrelated neurostructural, neuropathological, and behavioral changes associated with herpes simplex virus type 1 brain infection in mice. J Alzheimers Dis 30, 779-790.
53. Carter CJ (2010) APP, APOE, complement receptor 1, clusterin and PICALM and their involvement in the herpes simplex life cycle. Neurosci Lett 483, 96-100.
54. Piacentini R, Civitelli L, Ripoli C, Marcocci ME, De Chiara G, Garaci E, Azzena GB, Palamara AT, Grassi C (2011) HSV-1 promotes Ca2+-mediated APP phosphorylation and Aβ accumulation in rat cortical neurons. Neurobiol Aging 32, 2323.e13-26.
55. Alvarez G, Aldudo J, Alonso M, Santana S, Valdivieso F (2012) Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J Neurosci Res 90, 1020-1029.
56. Zambrano A, Solis L, Salvadores N, Cortés M, Lerchundi R, Otth C (2008) Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J Alzheimers Dis 14, 259-269.
57. Cribbs DH, Azizeh BY, Cotman CW, LaFerla FM (2000) Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer's A beta peptide. Biochemistry 39, 5988-5994.
58. Bearer EL (2012) HSV, axonal transport and Alzheimer's disease: In vitro and in vivo evidence for causal relationships. Future Virol 7, 885-899.
59. Satpute-Krishnan P, DeGiorgis JA, Bearer EL (2003) Fast anterograde transport of herpes simplex virus: Role for the amyloid precursor protein of Alzheimer's disease. Aging Cell 2, 305-318. Erratum in: Aging Cell 9 (2010), 454.
60. Shipley SJ, Parkin ET, Itzhaki RF, Dobson CB (2005) Herpes simplex virus interferes with amyloid precursor protein processing. BMC Microbiol 5, 48.
61. De Chiara G, Marcocci ME, Civitelli L, Argnani R, Piacentini R, Ripoli C, Manservigi R, Grassi C, Garaci E, Palamara AT (2010) APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells. PLoS One 5, e13989.
62. Cheng SB, Ferland P, Webster P, Bearer EL (2011) Herpes simplex virus dances with amyloid precursor protein while exiting the cell. PLoS One 6, e17966.
63. Santana S, Recuero M, Bullido MJ, Valdivieso F, Aldudo J (2012) Herpes simplex virus type I induces the accumulation of intracellular β-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells. Neurobiol Aging 33, e19-e33.
64. Tallóczy Z, Virgin HW 4th, Levine B (2006) PKRdependent autophagic degradation of herpes simplex virus type 1. Autophagy 2, 24-29.
65. Tallóczy Z, Jiang W, Virgin HW 4th, Leib DA, Scheuner D, Kaufman RJ, Eskelinen EL, Levine B (2002) Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci U S A 99, 190-195.
66. Itzhaki RF, Cosby SL, Wozniak MA (2008) Herpes simplex virus type 1 and Alzheimer's disease: The autophagy connection. J Neurovirol 14, 1-4.
67. Chou J, Chen JJ, Gross M, Roizman B (1995) Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A 92, 10516-10520.
68. Valyi-Nagy T, Dermody TS (2005) Role of oxidative damage in the pathogenesis of viral infections of the nervous system. Histol Histopathol 20, 957-967.
69. Santana S, Sastre I, Recuero M, Bullido MJ, Aldudo J (2013) Oxidative stress enhances neurodegeneration markers induced by herpes simplex virus type 1 infection in human neuroblastoma cells. PLoS One 8, e75842.
70. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA (2010) Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 59, 290-294.
71. Klapper PE, Cleator GM, Longson M (1984) Mild forms of herpes encephalitis. J Neurol Neurosurg Psychiatry 47, 1247-1250.
72. Marton R, Gotlieb-Stematsky T, Klein C, Lahat E, Arlazoroff A (1995) Mild form of acute herpes simplex encephalitis in childhood. Brain Dev 17, 360-361.
73. Peter JB, Sevall JS (2001) Review of 3200 serially received CSF samples submitted for type-specific HSV detection by PCR in the reference laboratory setting. Mol Cell Probes 15, 177-182.
74. Saldanha J, Sutton RN, Gannicliffe A, Farragher B, Itzhaki RF (1986) Detection of HSV1 DNA by in situ hybridisation in human brain after immunosuppression. J Neurol Neurosurg Psychiatry 49, 613-619.
75. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM (2005) HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci 46, 241-247.
76. Margolis TP, Elfman FL, Leib D, Pakpour N, Apakupakul K, Imai Y, Voytek C (2007) Spontaneous reactivation of herpes simplex virus type 1 in latently infected murine sensory ganglia. J Virol 81, 11069-11074.
77. Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP (2002) Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A 99, 978-983.
78. Martin C, Aguila B, Araya P, Vio K, Valdivia S, Zambrano A, Concha MI, Otth C (2014) Inflammatory and neurodegeneration markers during asymptomatic HSV-1 reactivation. J Alzheimers Dis 39, 849-859.
79. Itzhaki RF, Wozniak MA (2008) Herpes simplex virus type 1 in Alzheimer's disease: The enemy within. J Alzheimers Dis 13, 393-405.
80. Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ (2004) Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging 25, 619-627.
81. Varani S, Landini MP (2011) Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae 2, 6.
82. Lurain NS, Hanson BA, Martinson J, Leurgans SE, Landay AL, Bennett DA, Schneider JA (2013) Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis 208, 564-572.
83. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72, 2059-2064.
84. Aiello AE, Haan M, Blythe L, Moore K, Gonzalez JM, Jagust W (2006) The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc 54, 1046-1054.
85. Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, Gabrielli L, Licastro F (2014) Herpes virus in Alzheimer's disease: Relation to progression of the disease. Neurobiol Aging 35, 122-129.
86. Barnes LL, Capuano AW, Aiello AE, Turner AD, Yolken RH, Torrey EF, Bennett DA (2015) Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis 211, 230-237.
87. Tarter KD, Simanek AM, Dowd JB, Aiello AE (2014) Persistent viral pathogens and cognitive impairment across the life course in the third national health and nutrition examination survey. J Infect Dis 209, 837-844.
88. Lin WR, Wozniak MA, Cooper RJ, Wilcock GK, Itzhaki RF (2002) Herpesviruses in brain and Alzheimer's disease. J Pathol 197, 395-402.
89. Lin WR, Wozniak MA, Wilcock GK, Itzhaki RF (2002) Cytomegalovirus is present in a very high proportion of brains from vascular dementia patients. Neurobiol Dis 9, 82-87.
90. Koch S, Solana R, Dela Rosa O, Pawelec G (2006) Human cytomegalovirus infection and T cell immunosenescence: A mini review. Mech Ageing Dev 127, 538-543.
91. Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R (2007) Chronic herpesvirus reactivation occurs in aging. Exp Gerontol 42, 563-570.
92. Stowe RP, Peek MK, Cutchin MP, Goodwin JS (2012) Reactivation of herpes simplex virus type 1 is associated with cytomegalovirus and age. J Med Virol 84, 1797-1802.
93. Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-Brandstetter D, Würzner R, Schönitzer D, Grubeck-Loebenstein B (2005) Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 79, 3675-3683.
94. Westman G, Berglund D, Widén J, Ingelsson M, Korsgren O, Lannfelt L, Sehlin D, Lidehall AK, Eriksson BM (2014) Increased inflammatory response in cytomegalovirus seropositive patients with Alzheimer's disease. PLoS One 9, e96779.
95. Itzhaki RF, Klapper P (2014) Cytomegalovirus: An improbable cause of Alzheimer disease. J Infect Dis 209, 972-973.
96. Lurain NS, Hanson BA, Martinson J, Leurgans SE, Landay AL, Bennett DA, Schneider JA (2014) Reply to Itzhaki and Klapper. J Infect Dis 209, 974.
97. Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, Stuve O, Monson N, Racke MK, Jacobson S (2008) Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One 3, e2028.
98. Stone RC, Micali GA, Schwartz RA (2014) Roseola infantum and its causal human herpesviruses. Int J Dermatol 53, 397-403.
99. Yao K, Crawford JR, Komaroff AL, Ablashi DV, Jacobson S (2010) Review part 2: Human herpesvirus-6 in central nervous system diseases. J Med Virol 82, 1669-1678.
100. Licastro F, Carbone I, Raschi E, Porcellini E (2014) The 21st century epidemic: Infections as inductors of neurodegeneration associated with Alzheimer's disease. Immun Ageing 11, 22.
101. Landais E, Saulquin X, Houssaint E (2005) The human T cell immune response to Epstein-Barr virus. Int J Dev Biol 49, 285-292.
102. Kutok JL, Wang F (2006) Spectrum of Epstein-Barr virusassociated diseases. Annu Rev Pathol 1, 375-404.
103. Schmidt CW, Misko IS (1995) The ecology and pathology of Epstein-Barr virus. Immunol Cell Biol 73, 489-504.
104. Kleines M, Schiefer J, Stienen A, Blaum M, Ritter K, Häusler M (2011) Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity. Eur J Clin Microbiol Infect Dis 30, 1561-1569.
105. Connelly KP, DeWitt LD (1994) Neurologic complications of infectious mononucleosis. Pediatr Neurol 10, 181-184.
106. Pender MP, Burrows SR (2014) Epstein-Barr virus and multiple sclerosis: Potential opportunities for immunotherapy. Clin Transl Immunology 3, e27.
107. Contini C, Seraceni S, Cultrera R, Castellazzi M, Granieri E, Fainardi E (2010) Chlamydophila pneumoniae infection and its role in neurological disorders. Interdiscip Perspect Infect Dis 2010, 273573.
108. Moazed TC, Kuo CC, Grayston JT, Campbell LA (1998) Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 177, 1322-1325.
109. MacIntyre A, Abramov R, Hammond CJ, Hudson AP, Arking EJ, Little CS, Appelt DM, Balin BJ (2003) Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. J Neurosci Res 1, 740-750.
110. Hammerschlag MR, Kohlhoff SA (2012) Treatment of chlamydial infections. Expert Opin Pharmacother 13, 545-552.
111. Appelt DM, Roupas MR, Way DS, Bell MG, Albert EV, Hammond CJ, Balin BJ (2008) Inhibition of apoptosis in neuronal cells infected with Chlamydophila (Chlamydia) pneumoniae. BMC Neurosci 9, 13.
112. Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P (2004) Chlamydial persistence: Beyond the biphasic paradigm. Infect Immun 72, 1843-1855.
113. Rassu M, Cazzavillan S, Scagnelli M, Peron A, Bevilacqua PA, Facco M, Bertoloni G, Lauro FM, Zambello R, Bonoldi E (2001) Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions. Atherosclerosis 158, 73-79.
114. Di Pietro M, Filardo S, Cazzavillan S, Segala C, Bevilacqua P, Bonoldi E, D'Amore ES, Rassu M, Sessa R (2013) Could past Chlamydial vascular infection promote the dissemination of Chlamydia pneumoniae to the brain? J Biol Regul Homeost Agents 27, 155-164.
115. Arking EJ, Appelt DM, Abrams JT, Kolbe S, Hudson AP, Balin BJ (1999) Ultrastructural analysis of Chlamydia pneumoniae in the Alzheimer's brain. Pathogenesis (Amst) 1, 201-211.
116. Shima K, Kuhlenbäumer G, Rupp J (2010) Chlamydia pneumoniae infection and Alzheimer's disease: A connection to remember? Med Microbiol Immunol 199, 283-289.
117. Balin BJ, Little CS, Hammond CJ, Appelt DM, Whittum-Hudson JA, Gérard HC, Hudson AP (2008) Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J Alzheimers Dis 13, 371-380.
118. Nochlin D, Shaw CM, Campbell LA, Kuo CC (1999) Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease. Neurology 53, 1888.
119. Ring RH, Lyons JM (2000) Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain. J Clin Microbiol 38, 2591-2594.
120. Gieffers J, Reusche E, Solbach W, Maass M (2000) Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients. J Clin Microbiol 38, 881-882.
121. Taylor GS, Vipond IB, Paul ID, Matthews S, Wilcock GK, Caul EO (2002) Failure to correlate C. pneumoniae with late onset Alzheimer's disease. Neurology 59, 142-143.
122. Paradowski B, Jaremko M, Dobosz T, Leszek J, Noga L (2007) Evaluation of CSF-Chlamydia pneumoniae, CSFtau and CSF-Abeta42 in Alzheimer's disease and vascular dementia. J Neurol 254, 154-159.
123. Gérard HC, Wildt KL, Whittum-Hudson JA, Lai Z, Ager J, Hudson AP (2005) The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb Pathog 39, 19-26.
124. Boelen E, Steinbusch HW, Pronk I, Stassen FR (2007) Inflammatory responses following Chlamydia pneumoniae infection of glial cells. Eur J Neurosci 25, 753-760.
125. Hammond C, Little CS, Longo N, Procacci C, Appelt DM, Balin BJ (2006) Antibiotic alters inflammation in the mouse brain during persistent Chlamydia pneumoniae infection. In Alzheimer's Disease: New Advances, Iqbal K, Winblad B, Avila J, eds. Medimond, pp. 295-299.
126. Miklossy J (2011) Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation 8, 90.
127. Riviere GR, Riviere KH, Smith KS (2002) Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol 17, 113-118.
128. Miklossy J, Gern L, Darekar P, Janzer RC, Van der, Loos H (1995) Senile plaques, neurofibrillary tangles and neuropil threads contain DNA? J Spirochetal Tick Borne Dis 2, 1-5.
129. Miklossy J (1994) The spirochetal etiology of Alzheimer's disease: A putative therapeutic approach. In Alzheimer Disease: Therapeutic Strategies. Proceedings of the Third International Springfield Alzheimer Symposium, Giacobini E, Becker R, eds. Birkhauser, Boston, pp. 41-48.
130. Miklossy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L, Hurlimann J, Paster BJ (2004) Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis 6, 639-649; discussion 673-681.
131. Miklossy J (1998) Chronic inflammation and amyloidogenesis in Alzheimer's disease: Putative role of bacterial peptidoglycan, a potent inflammatory and amyloidogenic factor. Alzheimers Rev 3, 45-51.
132. Miklossy J, Darekar P, Gern L, Janzer RC, Bosman FT (1996) Bacterial peptidoglycan in neuritic plaque in Alzheimer's disease. Alzheimers Res 2, 95-100.
133. Ohnishi S, Koide A, Koide S (2000) Solution conformation and amyloid-like fibril formation of a polar peptide derived from a beta-hairpin in the OspA single-layer beta-sheet. J Mol Biol 11, 477-489.
134. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL (2008) Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation 5, 40.
135. Kamer AR, Craig RG, Pirraglia E, Dasanayake AP, Norman RG, Boylan RJ, Nehorayoff A, Glodzik L, Brys M, de Leon MJ (2009) TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. J Neuroimmunol 216, 92-97.
136. Stewart R, Sabbah W, Tsakos G, D'Aiuto F, Watt RG (2008) Oral health and cognitive function in the Third National Health and Nutrition Examination Survey (NHANES III). Psychosom Med 70, 936-941.
137. Noble JM, Borrell LN, Papapanou PN, Elkind MS, Scarmeas N, Wright CB (2009) Periodontitis is associated with cognitive impairment among older adults: Analysis of NHANES-III. J Neurol Neurosurg Psychiatry 80, 1206-1211.
138. Kuipers EJ (1997) Helicobacter pylori and the risk and management of associated diseases: Gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 11(Suppl 1), 71-88.
139. (1994) NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272, 65-69.
140. Papastergiou V, Georgopoulos SD, Karatapanis S (2014) Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 5, 392-399.
141. He C, Yang Z, Lu NH (2014) Helicobacter pylori-an infectious risk factor for atherosclerosis? J Atheroscler Thromb 21, 1229-1242.
142. Hahn M, Fennerty MB, Corless CL, Magaret N, Lieberman DA, Faigel DO (2000) Noninvasive tests as a substitute for histology in the diagnosis of Helicobacter pylori infection. Gastrointest Endosc 52, 20-26.
143. Burette A (1998) How (who?) and when to test or retest for H. pylori. Acta Gastroenterol Belg 61, 336-343.
144. Kountouras J, Tsolaki M, Boziki M, Gavalas E, Zavos C, Stergiopoulos C, Kapetanakis N, Chatzopoulos D, Venizelos I (2007) Association between Helicobacter pylori infection and mild cognitive impairment. Eur J Neurol 14, 976-982.
145. Kountouras J, Tsolaki M, Gavalas E, Boziki M, Zavos C, Karatzoglou P, Chatzopoulos D, Venizelos I (2006) Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology 66, 938-940.
146. Roubaud Baudron C, Letenneur L, Langlais A, Buissonnière A, Mégraud F, Dartigues JF, Salles N (2013) Personnes Agées QUID Study. Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agées QUID Study. J Am Geriatr Soc 61, 74-78.
147. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Grigoriadis N, Tsolaki M, Chatzopoulos D, Katsinelos P, Tzilves D, Zabouri A, Michailidou I (2009) Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease. Int J Neurosci 119, 765-777.
148. Wang XL, Zeng J, Feng J, Tian YT, Liu YJ, Qiu M, Yan X, Yang Y, Xiong Y, Zhang ZH, Wang Q, Wang JZ, Liu R (2014) Helicobacter pylori filtrate impairs spatial learning and memory in rats and increases β-amyloid by enhancing expression of presenilin-2. Front Aging Neurosci 6, 66.
149. Wang XL, Zeng J, Yang Y, Xiong Y, Zhang ZH, Qiu M, Yan X, Sun XY, Tuo QZ, Liu R, Wang JZ (2015) Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β. J Alzheimers Dis 43, 153-165.
150. Romero-Adrián TB, Leal-Montiel J, Monsalve-Castillo F, Mengual-Moreno E, McGregor EG, Perini L, Antúnez A (2010) Helicobacter pylori: Bacterial factors and the role of cytokines in the immune response. Curr Microbiol 60, 143-155.
151. Lagunes-Servin H, Torres J, Maldonado-Bernal C, Pérez-Rodríguez M, Huerta-Yépez S, Madrazo de la Garza A, M͡noz-Pérez L, Flores-Luna L, Ramón-García G, Camorlinga-Ponce M (2013) Toll-like receptors and cytokines are upregulated during Helicobacter pylori infection in children. Helicobacter 18, 423-432.
152. Kountouras J, Boziki M, Gavalas E, Zavos C, Grigoriadis N, Deretzi G, Tzilves D, Katsinelos P, Tsolaki M, Chatzopoulos D, Venizelos I (2009) Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol 256, 758-767.
153. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE (1998) Glial-neuronal interactions in Alzheimer's disease: The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 8, 65-72.
154. Griffin WS (2013) Neuroinflammatory cytokine signaling and Alzheimer's disease. N Engl J Med 368, 770-771.
155. Chami L, Checler F (2012) BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease. Mol Neurodegener 7, 52.
156. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci 8, 57-69.
157. Cai Z, Hussain MD, Yan LJ (2014) Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci 124, 307-321.
158. Floden AM, Li S, Combs CK (2005) Beta-amyloidstimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25, 2566-2575.
159. Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longe 2013, 316523.
160. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M (2004) Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 28, 67-78.
161. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, Kim S, Suh YH (2007) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32, 2393-2404.
162. Parker WD Jr (1991) Cytochrome oxidase deficiency in Alzheimer's disease. Ann N Y Acad Sci 640, 59-64.
163. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014)Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842, 1240-1247.
164. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5, e9505.
165. Lukiw WJ, Cui JG, Yuan LY, Bhattacharjee PS, Corkern M, Clement C, Kammerman EM, Ball MJ, Zhao Y, Sullivan PM, Hill JM (2010) Acyclovir or Aβ42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. Neuroreport 21, 922-927.
166. Wozniak MA, Frost AL, Preston CM, Itzhaki RF (2011) Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with Herpes simplex virus type 1. PLoS One 6, e25152.
167. Lynch MA (2014) The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology 141, 292-301.
168. Hickey WF (1991) Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1, 97-105.
169. Hickey WF (2001) Basic principles of immunological surveillance of the normal central nervous system. Glia 36, 118-124.
170. Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: The T cell code to breach the blood-brain barriers. Trends Immunol 33, 579-589.
171. Rogers J, Luber-Narod J, Styren SD, Civin WH (1988) Expression ofimmunesystem-associated antigensbycells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9, 339-349.
172. Itagaki S, McGeer PL, Akiyama H (1988) Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett 91, 259-264.
173. Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, Perreau V, Rogers J, Beach TG, Cotman CW (2007) Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging 28, 1821-1833.
174. McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Immune system response in Alzheimer's disease. Can J Neurol Sci 16(4 Suppl), 516-527.
175. Hartwig M (1995) Immune ageing and Alzheimer's disease. Neuroreport 6, 1274-1276.
176. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, Oda T, Tsuchiya K, Kosaka K (2002) Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 124, 83-92.
177. Town T, Tan J, Flavell RA, Mullan M (2005) T-cells in Alzheimer's disease. Neuromolecular Med 7, 255-264.
178. Pirttilä T, Mattinen S, Frey H (1992) The decrease of CD8-positive lymphocytes in Alzheimer's disease. J Neurol Sci 107, 160-165.
179. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT (2000) Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: In vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 108, 227-235.
180. Aloisi F, De Simone R, Columba-Cabezas S, Penna G, Adorini L (2000) Functional maturation of adult mouse resting microglia into an APC is promoted by granulocytemacrophage colony-stimulating factor and interaction with Th1 cells. J Immunol 164, 1705-1712.
181. Séguin R, Biernacki K, Prat A, Wosik K, Kim HJ, Blain M, McCrea E, Bar-Or A, Antel JP (2003) Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia 42, 36-45.
182. McQuillan K, Lynch MA, Mills KH (2010) Activation of mixed glia by Abeta-specific Th1 and Th17 cells and its regulation by Th2 cells. Brain Behav Immun 24, 598-607.
183. Kim HS, Whang SY, Woo MS, Park JS, Kim WK, Han IO (2004) Sodium butyrate suppresses interferon-gamma-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-alpha in microglia. J Neuroimmunol 151, 85-93.
184. Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA (2013) IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol 190, 2241-2251.
185. Murphy AC, Lalor SJ, Lynch MA, Mills KH (2010) Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 24, 641-651.
186. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B (1999) TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 13, 63-68.
187. Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, Laferla FM (2011) Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol 178, 2811-2822.
188. Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, Liang CR, Wang QH, Wang X, Cao HY, Yi X, Deng B, Liu CH, Xu J, Zhang LL, Gao CY, Xu ZQ, Zhang M, Wang L, Tan XL, Xu X, Zhou HD, Wang YJ (2014) A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol. doi: 10.1111/ene.12477 [Epub ahead of print] PubMed PMID: 24910016.
189. Mahley RW, Rall SC Jr (2000) Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1, 507-537.
190. Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G (2010) Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: A literature review. Lipids Health Dis 9, 8.
191. Itzhaki RF, Wozniak MA (2006) Herpes simplex virus type 1, apolipoprotein E, and cholesterol: A dangerous liaison in Alzheimer's disease and other disorders. Prog Lipid Res 45, 73-90.
192. Mahley RW, Ji ZS (1999) Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40, 1-16.
193. Koelle DM, Margaret A, Warren T, Schellenberg GD, Wald A (2010) APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sex Transm Infect 86, 202-206.
194. WuDunn D, Spear PG (1989) Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63, 52-58.
195. Gérard HC, Fomicheva E, Whittum-Hudson JA, Hudson AP (2008) Apolipoprotein E4 enhances attachment of Chlamydophila (Chlamydia) pneumoniae elementary bodies to host cells. Microb Pathog 44, 279-285.
196. Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, Morris CM, Burt AD, Donaldson PT (2006) Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 55, 715-718.
197. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL (2002) HCV Study Group. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 36, 456-463.
198. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX (1999) Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96, 12766-12771.
199. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8, 1-21.
200. Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, Hall C (1998) HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med 4, 1182-1184.
201. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A 105, 8718-8723.
202. Gale SC, Gao L, Mikacenic C, Coyle SM, Rafaels N, Murray Dudenkov T, Madenspacher JH, Draper DW, Ge W, Aloor JJ, Azzam KM, Lai L, Blackshear PJ, Calvano SE, Barnes KC, Lowry SF, Corbett S, Wurfel MM, Fessler MB (2014) APOε4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol 134, 127-134.
203. Fessler MB, Parks JS (2011) Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol 187, 1529-1535.
204. Okoro EU, Zhao Y, Guo Z, Zhou L, Lin X, Yang H (2012) Apolipoprotein E4 is deficient in inducing macrophage ABCA1 expression and stimulating the Sp1 signaling pathway. PLoS One 7, e44430.
205. Miyakawa T, Kimura T, Hirata S, Fujise N, Ono T, Ishizuka K, Nakabayashi J (2000) Role of blood vessels in producing pathological changes in the brain with Alzheimer's disease. Ann N Y Acad Sci 903, 46-54.
206. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
207. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296-302.
208. Dando SJ, Mackay-Sim A, Norton R, Currie BJ, St John JA, Ekberg JA, Batzloff M, Ulett GC, Beacham IR (2014) Pathogens penetrating the central nervous system: Infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev 27, 691-726.
209. Pan W, Stone KP, Hsuchou H, Manda VK, Zhang Y, Kastin AJ (2011) Cytokine signaling modulates blood-brain barrier function. Curr Pharm Des 17, 3729-3740.
210. van Sorge NM, Doran KS (2012) Defense at the border: The blood-brain barrier versus bacterial foreigners. Future Microbiol 7, 383-394.
211. Minagar A, Alexander JS (2003) Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9, 540-549.
212. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, Zlokovic BV (2015) Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab. doi: 10.1038/jcbfm.2015.44 [Epub ahead of print] PubMed PMID: 25757756.
213. Zhang F, Jiang L (2015) Neuroinflammation in Alzheimer's disease. Neuropsychiatr Dis Treat 11, 243-256.
214. Labus J, Häckel S, Lucka L, Danker K (2014) Interleukin-1β induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMECbased in vitro blood-brain barrier model. J Neurosci Methods 228, 35-45.
215. Kim KS (2008) Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Microbiol 6, 625-634.
216. Banks WA (2005) Blood-brain barrier transport of cytokines: A mechanism for neuropathology. Curr Pharm Des 11, 973-984.
217. Simi A, Tsakiri N, Wang P, Rothwell NJ (2007) Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 35, 1122-1126.
218. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8, 205-216.
219. Kim YS, Joh TH (2012) Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders. Biomol Ther (Seoul) 20, 133-143.
220. Syvänen S, Eriksson J (2013) Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci 4, 225-237.
221. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BN (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135, 181-189.
222. Gheorghiu M, Enciu AM, Popescu BO, Gheorghiu E (2014) Functional and molecular characterization of the effect of amyloid-β42 on an in vitro epithelial barrier model. J Alzheimers Dis 38, 787-798.
223. Burgmans S, van de Haar HJ, Verhey FR, Backes WH (2013) Amyloid-β interacts with blood-brain barrier function in dementia: A systematic review. J Alzheimers Dis 35, 859-873.
224. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516.
225. Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW (2010) Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother 54, 1146-1151.
226. Lycke J, Malmeström C, Ståhle L (2003) Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother 47, 2438-2441.
227. Pouplin T, Pouplin JN, Van Toi P, Lindegardh N, Rogier van Doorn H, Hien TT, Farrar J, Török ME, Chau TT (2011) Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother 55, 3624-3626.
228. Friedman JE, Zabriskie JB, Plank C, Ablashi D, Whitman J, Shahan B, Edgell R, Shieh M, Rapalino O, Zimmerman R, Sheng D (2005) A randomized clinical trial of valacyclovir in multiple Sclerosis. Mult Scler 11, 286-295.
229. Tyring SK, Baker D, Snowden W (2002) Valacyclovir for herpes simplex virus infection: Long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 186(Suppl 1), S40-S46.
230. Prasad KM, Eack SM, Keshavan MS, Yolken RH, Iyengar S, Nimgaonkar VL (2013) Antiherpes virus-specific treatment and cognition in schizophrenia: A test-of-concept randomized double-blind placebo-controlled trial. Schizophr Bull 39, 857-866.
231. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M (2010) Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 7, 90.
232. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wei X, Farlow M, Sommer N, Oertel WH (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75, 1472-1474.
233. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30, 1728-1736.
234. Relkin N (2014) Intravenous immunoglobulin for Alzheimer's disease. Clin Exp Immunol 178(Suppl 1), 27-29.
235. Kohl S, Loo LS (1986) In vitro and in vivo antibodydependent cellular cytotoxicity of intravenous immunoglobulin G preparations against herpes simplex virus. Rev Infect Dis 8(Suppl 4), S446-S448.
236. Erlich KS, Mills J (1986) Passive immunotherapy for encephalitis caused by herpes simplex virus. Rev Infect Dis 8(Suppl 4), S439-S445.
237. Masci S, DeSimone C, Famularo G, Gravante M, Ciancarelli M, Andreassi M, Amerio P, Santini G (1995) Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: A clinical and immunological study. Immunopharmacol Immunotoxicol 17, 33-47.
238. Wozniak MA, Itzhaki RF (2013) Intravenous immunoglobulin reduces β amyloid and abnormal tau formation caused by herpes simplex virus type 1. J Neuroimmunol 257, 7-12.
239. Lin WR, Jennings R, Smith TL, Wozniak MA, Itzhaki RF (2001)Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol Aging 22, 699-703.
240. Field HJ, Vere Hodge RA (2013) Recent developments in anti-herpesvirus drugs. Br Med Bull 106, 213-249.
241. Lancini D, Faddy HM, Flower R, Hogan C (2014) Cytomegalovirus disease in immunocompetent adults. Med J Aust 201, 578-580.
242. Cohen JI (2009) Optimal treatment for chronic active Epstein-Barr virus disease. Pediatr Transplant 13, 393-396.
243. Prichard MN, Whitley RJ (2014) The development of new therapies for human herpesvirus 6. Curr Opin Virol 9, 148-153.
244. Nau R, Sörgel F, Eiffert H (2010) Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23, 858-883.
245. Yamaguchi H, Friedman H, Yamamoto M, Yasuda K, Yamamoto Y (2003) Chlamydia pneumoniae resists antibiotics in lymphocytes. Antimicrob Agents Chemother 47, 1972-1975.
246. Carter JD, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, Valeriano J, Stanich JA, Oszust C, Gerard HC, Hudson AP (2010) Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: A doubleblind, placebo-controlled, prospective trial. Arthritis Rheum 62, 1298-1307.
247. Sadarangani SP, Estes LL, Steckelberg JM (2015) Nonanti-infective effects of antimicrobials and their clinical applications: A review. Mayo Clin Proc 90, 109-127.
248. Kim HS, Suh YH (2009) Minocycline and neurodegenerative diseases. Behav Brain Res 196, 168-179.
249. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M (2001) Anti-amyloidogenic activity of tetracyclines: Studies in vitro. FEBS Lett 487, 404-407.
250. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK (1992) Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 29, 719-724.
251. Qosa H, Abuznait AH, Hill RA, Kaddoumi A (2012) Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 31, 151-165.
252. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, Davidson W, McDougall A, Gnarpe J, O'DONNell M, Chernesky M (2004) A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J AmGeriatr Soc 52, 381-387.
253. Molloy DW, Standish TI, Zhou Q, Guyatt G (2013) DARAD Study Group. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: The DARAD trial. Int J Geriatr Psychiatry 28, 463-470.
254. Borg R, Dotevall L, Hagberg L, Maraspin V, Lotric-Furlan S, Cimperman J, Strle F (2005) Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 37, 449-454.
255. Ljøstad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, Mygland A (2008) Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: A multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 7, 690-695.
256. Abramson IJ, Smibert RM (1971) Bactericidal activity of antimicrobial agents for treponemes. Br J Vener Dis 47, 413-418.
257. Kikutani T, Yoneyama T, Nishiwaki K, Tamura F, Yoshida M, Sasaki H (2010) Effect of oral care on cognitive function in patients with dementia. Geriatr Gerontol Int 10, 327-328.
258. Feres M, Figueiredo LC, Soares GM (2015) Faveri M. Systemic antibiotics in the treatment of periodontitis. Periodontol 2000 67, 131-186.
259. Feres M, Haffajee AD, Allard K, Som S, Socransky SS (2001) Change in subgingival microbial profiles in adult periodontitis subjects receiving either systemically-administered amoxicillin or metronidazole. J Clin Periodontol 28, 597-609.
260. Haffajee AD, Patel M, Socransky SS (2008) Microbiological changes associated with four different periodontal therapies for the treatment of chronic periodontitis. Oral Microbiol Immunol 23, 148-157.
261. Haffajee AD, Torresyap G, Socransky SS (2007) Clinical changes following four different periodontal therapies for the treatment of chronic periodontitis: 1-year results. J Clin Periodontol 34, 243-253.
262. Oteo A, Herrera D, Figuero E, O'Connor A, González I, Sanz M (2010) Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis associated periodontitis: A pilot study. J Clin Periodontol 37, 1005-1015.
263. Dastoor SF, Travan S, Neiva RF, Rayburn LA, Giannobile WV, Wang HL (2007) Effect of adjunctive systemic azithromycin with periodontal surgery in the treatment of chronic periodontitis in smokers: A pilot study. J Periodontol 78, 1887-1896.
264. Feres M, Haffajee AD, Allard K, Som S, Goodson JM, Socransky SS (2002) Antibiotic resistance of subgingival species during and after antibiotic therapy. J Clin Periodontol 29, 724-735.
265. O'Connor A, Gisbert JP, McNamara D, O'Morain C (2011) Treatment of Helicobacter pylori infection 2011. Helicobacter 16(Suppl 1), 53-58.
266. Graham DY (2015) Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits. Gastroenterology 148, 719-731.
267. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Chatzigeorgiou S, Katsinelos P, Grigoriadis N, Giartza-Taxidou E, Venizelos I (2010) Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol 23, 199-204.
268. Yolken R (2004) Viruses and schizophrenia: A focus on herpes simplex virus. Herpes 11(Suppl 2), 83A-88A.
269. Taller AM, Asher DM, Pomeroy KL, Eldadah BA, Godec MS, Falkai PG, Bogert B, Kleinman JE, Stevens JR, Torrey EF (1996) Search for viral nucleic acid sequences in brain tissues of patients with schizophrenia using nested polymerase chain reaction. Arch Gen Psychiatry 53, 32-40.
270. Itzhaki RF, Wozniak MA (2012) Could antivirals be used to treat Alzheimer's disease? Future Microbiol 7, 307-309.
271. Baringer JR, Pisani P (1994) Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann Neurol 36, 823-829.
272. Gordon L, McQuaid S, Cosby SL (1996) Detection of herpes simplex virus (types 1 and 2) and human herpesvirus 6 DNA in human brain tissue by polymerase chain reaction. Clin Diagn Virol 6, 33-40.
273. Bertrand P, Guillaume D, Hellauer L, Dea D, Lindsay J, Kogan S, Gauthier S, Poirier J (1993) Distribution of herpes simplex virus type 1 DNA in selected areas of normal and Alzheimer's disease brains: A PCR study. Neurodegeneration 2, 201-208.
274. Cheon MS, Bajo M, Gulesserian T, Cairns N, Lubec G (2001) Evidence for the relation of herpes simplex virus type1 to Down syndrome and Alzheimer's disease. Electrophoresis 22, 445-448.